Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.

Cell death & disease - 27 Jan 2020

González-Rodríguez Patricia, Engskog-Vlachos Pinelopi, Zhang Hanzhao, Murgoci Adriana-Natalia, Zerdes Ioannis, Joseph Bertrand

Abstract excerpt

Inactivating mutations in the SETD2 gene, encoding for a nonredundant histone H3 methyltransferase and regulator of transcription, is a frequent molecular feature in clear cell renal cell carcinomas (ccRCC). SETD2 deficiency is associated with recurrence of ccRCC and bears low prognostic values. Targeting autophagy, a conserved catabolic process with critical functions in maintenance of cellular homeostasis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autophagy-Related Protein 5

Share to Carcinoma, Renal Cell

Share to Histone-Lysine N-Methyltransferase

Share to Histones

Share to Kidney Neoplasms

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 31988284
DOI: 10.1038/s41419-020-2266-x
PMCID: PMC6985262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.PMID 31988284Read ↗

Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.Semantic proximity Read ↗

SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formationSemantic proximity Read ↗

Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCCSemantic proximity Read ↗

SETD2 methyltransferase activity aids gene definition by promoting correct transcription initiation and terminationSemantic proximity Read ↗

SETD2: an epigenetic modifier with tumor suppressor functionality.Semantic proximity Read ↗

MiR-182-5p Inhibits the Tumorigenesis of clear cell renal cell carcinoma by Repressing UBE2TSemantic proximity Read ↗

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.Semantic proximity Read ↗

[Research progress on the expression and carcinogenic mechanisms of SETD2 in malignant tumors].Semantic proximity Read ↗

Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.Semantic proximity Read ↗

SETD2 methyltransferase activity promotes correct transcription initiation and termination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.